Vaxcyte Inc (Nasdaq: PCVVX), a next-generation vaccine company in Foster City, CA, USA, has announced the closing of its initial public offering. The aggregate gross proceeds from the offering were $287.5 million before deducting commissions and expenses. The shares began trading on Nasdaq on June 12, 2020.  One of Vaxcyte’s projects, a vaccine to prevent Group A Strep infections, is funded by CARB-X.